Has Payam Vahedifar received payments from drug or device companies?

Yes. Drug and device makers reported $3,455 in general payments to Payam Vahedifar across 96 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Payam Vahedifar did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Payam Vahedifar come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Payam Vahedifar

Pain Medicine · Encino, CANPI 1861473464

Payments from drug & device makers

$3,455in general payments, 2019–2025

Across 96 payments — averaging $35.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Medtronic$2K
Boston Scientific$586
Nevro Corp.$150
Collegium Pharmaceutical, Inc.$140
Amgen$117
Saluda Medical Americas, Inc.$113
plus $475 from 12 others

$1,150in research payments, 2019–2025

Across 3 payments — averaging $383.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Medtronic$1K

What the payments were for

Travel & lodging$63418%
Food & beverage$2,82182%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Medtronic(2 entities)	26	$1,874
Boston Scientific	30	$586
Nevro Corp.	2	$150
Collegium Pharmaceutical, Inc.	7	$140
Amgen(2 entities)	6	$117
Saluda Medical Americas, Inc.	3	$113
AstraZeneca	3	$75
Daiichi Sankyo Inc.	4	$67
Pacira Therapeutics, Inc.	1	$50
Novo Nordisk	2	$48
Biodelivery Sciences International, Inc.	3	$41
Biohaven Pharmaceutical Holding Company Ltd.	1	$33
Pfizer	2	$30
Sentynl Therapeutics, Inc.	2	$29
AbbVie	1	$28
Sequel Med Tech, LLC	1	$27
Abbott	1	$23
Vifor Pharma, Inc.	1	$23

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

INTELLIS$1,238
VANTA ADAPTIVESTIM$129
GENERAL PAIN MANAGEMENT$105
Senza Spinal Cord Stimulation System$101

How this compares

$3,455 in reported general payments places this provider in the 60th percentile of 840 pain medicine providers in California.

See all pain medicine providers in California →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
PercocetOxycodone Hcl/Acetaminophen	14	$93,366
Xtampza ErOxycodone Myristate	52	$49,546
OxycontinOxycodone Hcl	44	$32,408
Fentanyl	58	$15,832
ValiumDiazepam	14	$15,733
RoxicodoneOxycodone Hcl	14	$12,696
Oxycodone Hcl	330	$9,821
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen	232	$5,826
SavellaMilnacipran Hcl	12	$5,700
Diclofenac Sodium	78	$4,499
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen	125	$4,357
ButransBuprenorphine	13	$3,938
Morphine Sulfate ErMorphine Sulfate	59	$2,967
Gabapentin	100	$2,482
Lidocaine	16	$2,162

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er	$140	$49,54652 claims
AbbVieSavella	$28	$5,70012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 840 pain medicine providers in California.

Other pain medicine in Encino

Jeffrey GlaserEncino$165K
Eric GrigsbyNapa$3.2M
Jason PopeSanta Rosa$2.8M
Javid GhandehariSanta Monica$2.7M
Alexander HerselThousand Oaks$2.1M
Krishnan ChakravarthyTemecula$1.9M
Kasra AmirdelfanWalnut Creek$1.7M
Ramana NaiduLarkspur$1.6M
Foead GeulaStudio City$1.3M
Xiang QianRedwood City$941K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →